Esperion Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.6 Mil. Esperion Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $264.6 Mil. Esperion Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-455.0 Mil.
Esperion Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -0.58.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Esperion Therapeutics's Debt-to-Equity or its related term are showing as below:
ESPR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.93 Med: 0 Max: 0.08
Current: -0.59
During the past 13 years, the highest Debt-to-Equity Ratio of Esperion Therapeutics was 0.08. The lowest was -1.93. And the median was 0.00.
Esperion Therapeutics Debt-to-Equity Historical Data
The historical data trend for Esperion Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Esperion Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
0.08 |
-1.93 |
-1.32 |
-0.81 |
-0.59 |
|
Esperion Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-0.81 |
-0.79 |
-0.71 |
-0.64 |
-0.59 |
Competitive Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Esperion Therapeutics Debt-to-Equity Distribution
For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Esperion Therapeutics's Debt-to-Equity falls into.
Esperion Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Esperion Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Esperion Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Esperion Therapeutics (Esperion Therapeutics) Business Description
Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.
Executives
| Eric Warren |
officer: Chief Commercial Officer |
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
| J Martin Carroll |
director |
C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873 |
| Stephen Rocamboli |
director |
C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019 |
| Sheldon L. Koenig |
officer: Chief Operating Officer |
C/O PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
| Joanne M. Foody |
officer: Chief Medical Officer |
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
| Benjamin Looker |
officer: General Counsel |
C/O TRILLIUM THERAPEUTICS INC., 2488 DUNWIN DRIVE, MISSISSAUGA A6 L5L 1J9 |
| Benjamin Halladay |
officer: Chief Financial Officer |
ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
| Fischer Seth H.z. |
director |
C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121 |
| Biotech Target N V |
10 percent owner |
ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000 |
| Alan Fuhrman |
director |
C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121 |
| Timothy M Mayleben |
director, officer: Pres & Chief Executive Officer |
3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108 |
| Ashley Hall |
officer: Chief Development Officer |
C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI 48108 |
| Tracy M Woody |
director |
2656 CROSSPARK ROAD, SUITE 100, CORALVILLE IA 52241 |
| Richard Bartram |
officer: Chief Financial Officer |
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108 |
| Nicole Vitullo |
director, 10 percent owner |
3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121 |
Esperion Therapeutics (Esperion Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ESPR has been successfully added to your